Experience in the Treatment of Patients with Sexual Disorders and Lower Urinary Tract Symptoms After Surgical Treatment of Benign Prostatic Hyperplasia
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The aim of the research: the choice of treatment for patients with sexual disorders (SD) and lower urinary tract symptoms (LUTS) after surgical treatment of benign prostatic hyperplasia (BPH).
Materials and methods. There were examined 270 patients, who were divided into two groups: 75 patients with BPH stage I1II who received medical therapy and 160 after surgical treatment (85 and 75 patients undergoing TUPR and the different types of prostatectomy, respectively). The period between surgery and inclusion in the study was 1-2 months. In addition, the study included 35 healthy men who made up the reference group. All patients received basic therapy according to the standards of the European Association of urology, guidelines regarding healthy lifestyle, avoiding harmful habits, diet and physical therapy methods. In addition, patients received therapy with inhibitors of phosphodiesterase of 5-th type, tailor-made preparations and metabolic stimulation therapy, drugs to improve blood flow of blood to the cavernous bodies, or tools that reduce the outflow of venous blood from them.
Results. Treatment results were assessed by the dynamics of changes in LUTS, objective information about the functional status after 3, 6 and 12 months. Dynamics of indicators of SD, psycho1emotional status was assessed at 1, 3, 6 and 12 months.
Conclusion. Established the identity of the nature of the assessment of men from both groups’ satisfaction with the treatment was a linear relationship between time and criteria such as overall satisfaction with desire to continue it, with confidence and pleasure, sexual opportunities, quality of erections.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Колесник Н.А. Теория и практика доказательной медицины / Н.А. Колесник, В.Н. Непомнящий, Е.С. Самусева. – Київ: Полиграфплюс, 2006. – 200 с.
Пасєчніков С.П. Принципи класифікації. Діагностики та лікування доброякісної гіперплазії передміхурової залози / С.П. Пасєчніков // Мед. аспекты здоров’я мужчины. – 2015. – № 4 (19). – С. 5-10.
Трайш А.М. Тестостерон и эректильная дисфункция: от фундаментальних исследований к новой клинической парадигме лечения мужчин с возрастным андрогенным дефицитом и эректильной дисфункцией / А.М. Трайш, Н.Н. Ким, И. Голдстейн // Здоровье мужчины. – 2008. – № 1. – С. 24-36.
European Association of Urology. Guidelines on Male Sexual Dysfunction: Erectile Dysfunction and Premature Ejaculation, 2015. – 21 p.
Giuliano F. et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia / F. Giuliano [et al.] // Eur. Urol. – 2013. – V. 63. – P. 506-616.
Rosen R.C. Lower urinary tract symptoms and male sexual dysfunction: the Multi-National surgery of the ageing male (MSAM-7) / R.C. Rosen, J. Altwein, P. Boyl [et al.] // Eur. Urol. – 2003. – V. 44. – P. 637-649.
Seki N. Prevalence and preference with regard to various surgical treatment for benign prostatic hypertrophy: a survey for the Japanese endourology and ESWL society member / N. Seki, S. Naito, S. Oshima // Nippon Hinyokika Gakkai Zasshi. – 2003. – V. 94, № 4. – P. 495-502.
Donatucci C.F. Tabalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1year, open-label extension study / C.F. Donatucci, G.B. Brock, E.R. Goldfischer [et al.] // BJU Int. – 2011. – V. 107 (7). – P. 1110-6.
Green R. Orally disintegrating vardenafil tablets for the treatment of erectile dysfunction: efficacy, safety, and patient acceptability / R. Green, R.W. Hicks // Patient Prefer Adherence. – 2011. – V. 5. – P. 181-185.
Nishikawa G. Prostatic penetration of meropenem гhumans, and dosage considerations hiprostatitis based on a site-specific pharmacokinetic/pharmacodynamic evaluation / G. Nishikawaa, K. Ikawab, K. Nakamura [et al.] // Int. J. Antimicrobial Agents. – 2013. – V. 41. – P. 267-271.
Shabsigh R. Testosterone therapy in erectile dysfunction / R. Shabsigh //Aging Male. – 2004. – V. 7. – P. 312-318.
